by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : March 2005
product news over-the-counter products Real-life results for Xenical A major study published in this month’s Diabetes, Obesity and Metabolism provides confirmation of the effectiveness of Xenical (orlistat) with participants losing an average of 10.8 kilograms in a real-life setting. This post-marketing surveillance investigation involved more than 15,000 overweight men and women, and is the first to evaluate Xenical in a primary healthcare setting versus controlled clinical trial conditions. The average weight loss after seven months of treatment with Xenical was about 11 per cent of body weight in both men and women. This is in marked contrast to the low weight loss over one year with popular diets reported recently in the Journal of the American Medical Association: 2.1kg for those on the Atkins diet, 3.2kg for the Zone diet, 3kg for Weight Watchers and 3.3kg for the Ornish (fat restriction) diet. Nicabate gives pharmacy wheels T Back support N ¦ Power up G ERRY White Chemist Kin Kora in Gladstone, Queensland, is the winner of the NicabateCQ Smart Car, provided by NicabateCQ. The brand gave away a total of $15,000 in cash prizes and the Smart Car major prize, as part of its 2004 CQ Partnership Programme. Pharmacist Jeff McEvoy said he couldn’t wait to congratulate his staff on winning the major prize. ‘The CQ Partnership Programme is a terrific program,’ he said. ‘Not only do customers respond well, but it has helped increase our NRT sales.’ Mandie Smart, GlaxoSmithKline Consumer Healthcare Group Brand Manager for NicabateCQ said the CQ Partnership Programme has been a great success in 2004, with an increase of 21 per cent in the number of CQ enrolments and an increase of 11.6 per cent in NicabateCQ sales compared to the previous year. EW from Futuro is the Stabilising Back Support, which helps relieve back pain and provides users with strong, comfortable lower back support. The product uses ‘comfort cushions’ to apply soft, gentle pressure to muscles, and is discreet enough to be worn under clothing. ¦ ILLETTE has introduced the M3Power, a powered wet shaving system for men. The product delivers Gillette’s best shave yet, via gentle pulses that stimulate hair upward and away from the skin, making it easier to shave more thoroughly. The new product will be heavily supported via innovative teaser campaigns, product sampling, outdoor advertising and a media campaign. M3Power will be introduced alongside ¦ a new shaving gel, MACH3Turbo Gel, which contains aloe and vitamin E to soothe and nourish skin. ¦ 182 ? THE AUSTRALIAN JOURNAL OF PHARMACY VOL 86 MARCH 2005